Compare Jumia Technologies AG - ADR (JMIA) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Pfizer Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.48 (market cap $865.90M), while Pfizer Inc trades at $28.1 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 183.1× Jumia Technologies AG - ADR's market cap, and Pfizer Inc pays a 6.18% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Pfizer Inc for 158 Days on average.
| JMIA | PFE | |
|---|---|---|
Market Cap | $865.90M | $158.56B |
Volume | 1,695,227 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $29.02 |
52-Week Low | $5.69 | $23.67 |
Typical Hold Time | 28 Days | 158 Days |
Enterprise Value | $831.54M | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.74, down 0.88% with a bearish technical signal despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent $50M capital injection and operational improvements support the path toward EBITDA breakeven by year-end 2026.
Investment outlook balances analyst bullishness (71% buy ratings, $12 consensus target) against persistent profitability challenges. Key opportunities include African e-commerce growth and cost optimization, while risks center on execution timeline and competitive pressures. The stock offers speculative upside if turnaround milestones are met.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
